Peptides in biohacking: What BPC-157 and Thymosin show in studies

Peptides like BPC-157 and TB-500 circulate in biohacking circles as quick regeneration aids for joints and muscles. But most studies were conducted in animals — what is transferable to humans remains scientifically uncertain.

What peptides are and why they became popular in the biohacking scene

Peptides are short chains of amino acids — smaller than proteins, but structurally related. In the body, many endogenous peptides act as signaling molecules: hormones, growth factors, and neurotransmitters are largely peptides. In medicine, synthetic peptides are already used as drugs, for example insulin or certain cancer therapeutics.

Two peptides spread particularly widely in biohacking: BPC-157, a peptide isolated from a stomach protein, and TB-500, a synthetic variant of the endogenous peptide Thymosin Beta-4. Both are used in the community primarily for faster healing of tendon, muscle, and joint injuries.

What BPC-157 showed in animal studies

BPC-157 was studied primarily in rat models. The research group of Sikiric at the University of Zagreb published numerous papers showing accelerated growth of tendons, ligaments, and muscles following BPC-157 injection. Gastroprotective effects were also described — a reduction in gastric ulcers and inflammatory bowel changes in animal models.

Mechanistically, BPC-157 is said to activate the growth factor VEGF, thereby stimulating the formation of new blood vessels. It is also claimed to influence the nitric oxide system and inflammatory responses.

The fundamental problem: no controlled human studies

For BPC-157 and TB-500, there are as of today no completed, published randomized controlled studies in healthy or injured humans. All the popular evidence is based on animal studies and case reports from the biohacking community.

Animal studies are an important step in research, but no guarantee of efficacy in humans. Numerous substances that show impressive results in rodents have not worked in humans — or have proven harmful. Without human studies, the benefit-risk ratio for BPC-157 cannot be validly assessed.

Legal and safety framework

BPC-157 is not approved as a medicinal product in Switzerland, Germany, or Austria. It is neither recognized as a food supplement nor regulated in a way that guarantees consistent purity and dosage. Substances obtained through grey markets carry considerable quality and contamination risks.

TB-500 is on the WADA prohibited list and constitutes a doping substance for athletes competing in sport. Using it in unregulated injectable forms carries additional infection and dosing risks. Everyone who engages with this topic should be aware of these facts.

The YUTHI app and the topic of peptides

YUTHI does not recommend unapproved substances. This article serves as a factual assessment of a topic that is present in the biohacking community — so you know what is established and what is not.

If you have injuries or recovery issues, you can document your workouts, pain patterns, and recovery times in the YUTHI app, providing a well-founded basis for conversations with specialists. Well-established measures such as targeted training, adequate sleep, and sufficient protein have a significantly stronger evidence base here than injectable peptides.

Sources

• Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16):1612–1632, 2011.
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9):421–429, 2005.
• Seiwerth S et al. BPC 157 and Standard Angiogenic Growth Factors. Journal of Physiology Paris, 108(4–6):270–286, 2014.